Fluorometholone

Fluorometholone Reactions 1680, p142 - 2 Dec 2017 Cushing’s syndrome: case report A 4 years-old boy developed Cushing’s syndrome (CS) during treatment with fluorometholone eye drops. The boy presented with the complaint of rapid weight gain. He had a BMI of 18.1 with a height of 99.9cm and a weight of 18.1kg. On presentation, his examination demonstrated moon facies. He had a diagnosis of allergic conjunctivitis and he had been receiving fluorometholone containing eye drops (0.1% solution) and netilmicin for one month. He was using 3 5 drops of fluorometholone a day. At basal hormonal evaluation, his cortisol level was 0.38 µg/dL and ACTH level was <5 pg/mL. An ACTH stimulation test was performed and peak cortisol level of 11.5 µg/dL was obtained at 60 minutes. These findings were consistent with adrenal insufficiency. Thereafter, the boy was recommended for hydrocortisone therapy, but his family was reluctant to hydrocortisone th treatment. Basal hormonal evaluation at the 4 month, showed the normal functioning of pituitary-adrenal axis. Additionally, his facial appearance became normal. Author comment: "In our patient, CS developed following the use of fluorometholone, a relatively less potent steroid compared to these other steroids." "Although eyedrops containing potent glucocorticoids may lead to CS, fluorometholone, a relatively less potent steroid, may also cause the syndrome, as in our case." Ustyol A, et al. Cushing’s syndrome caused by use of synthetic ocular steroid. Journal of Clinical Pharmacy and Therapeutics 42: 780-782, No. 6, Dec 2017. Available from: URL: http://doi.org/10.1111/jcpt.12573 - Turkey 803284590 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Fluorometholone

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/fluorometholone-OkScOb5a2L
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39073-4
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p142 - 2 Dec 2017 Cushing’s syndrome: case report A 4 years-old boy developed Cushing’s syndrome (CS) during treatment with fluorometholone eye drops. The boy presented with the complaint of rapid weight gain. He had a BMI of 18.1 with a height of 99.9cm and a weight of 18.1kg. On presentation, his examination demonstrated moon facies. He had a diagnosis of allergic conjunctivitis and he had been receiving fluorometholone containing eye drops (0.1% solution) and netilmicin for one month. He was using 3 5 drops of fluorometholone a day. At basal hormonal evaluation, his cortisol level was 0.38 µg/dL and ACTH level was <5 pg/mL. An ACTH stimulation test was performed and peak cortisol level of 11.5 µg/dL was obtained at 60 minutes. These findings were consistent with adrenal insufficiency. Thereafter, the boy was recommended for hydrocortisone therapy, but his family was reluctant to hydrocortisone th treatment. Basal hormonal evaluation at the 4 month, showed the normal functioning of pituitary-adrenal axis. Additionally, his facial appearance became normal. Author comment: "In our patient, CS developed following the use of fluorometholone, a relatively less potent steroid compared to these other steroids." "Although eyedrops containing potent glucocorticoids may lead to CS, fluorometholone, a relatively less potent steroid, may also cause the syndrome, as in our case." Ustyol A, et al. Cushing’s syndrome caused by use of synthetic ocular steroid. Journal of Clinical Pharmacy and Therapeutics 42: 780-782, No. 6, Dec 2017. Available from: URL: http://doi.org/10.1111/jcpt.12573 - Turkey 803284590 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off